<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890981</url>
  </required_header>
  <id_info>
    <org_study_id>20080747</org_study_id>
    <nct_id>NCT00890981</nct_id>
  </id_info>
  <brief_title>A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab</brief_title>
  <official_title>A HR-pQCT Study in Postmenopausal Women Previously Treated With Denosumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the combined effect of denosumab treatment and discontinuation on cortical
      thickness at the distal radius by High Resolution-Peripheral Quantitative Computed Tomography
      (HR-pQCT). Participants randomized to either denosumab or placebo in the 20050179
      (NCT00293813) study who completed that study (ie, attended an end of study visit) can be
      included in this study. At least 12 months should have elapsed since the patient's 20050179
      end of study visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change from the 20050179 Baseline in cortical thickness at the distal radius as determined by high-resolution peripheral quantitative computed tomography (HR-pQCT) at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change from the 20050179 Baseline in total BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change from the 20050179 Baseline in cortical BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change from the 20050179 Baseline in trabecular BMD at the distal radius as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change from the 20050179 Baseline in cortical thickness at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change from the 20050179 Baseline in total BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change from the 20050179 Baseline in cortical BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change from the 20050179 Baseline in trabecular BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change of distal 1/3 radius BMD from the 20050179 Baseline as determined by dual energy X-ray absorptiometry (DXA) at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change of ultradistal radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since last the subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Total Radius BMD From the Parent Study Baseline by DXA</measure>
    <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
    <description>Percent change of total radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Value of Serum Type I C-telopeptide</measure>
    <time_frame>Day 1</time_frame>
    <description>Actual value of Serum Type I C-telopeptide measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Value of Procollagen Type 1 N-terminal Peptide</measure>
    <time_frame>Day 1</time_frame>
    <description>Actual value of Type 1 N-terminal Peptide as measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Low Bone Mass</condition>
  <condition>Low Bone Mineral Density</condition>
  <condition>Osteoporosis</condition>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high-resolution peripheral quantitative computed tomography (HR-pQCT)</intervention_name>
    <description>Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual energy X-ray absorptiometry (DXA)</intervention_name>
    <description>Bone densitometry assessments of the forearm by DXA on day 1.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab 60 mg subcutaneously every 6 months in the previous study</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to denosumab subcutaneously every 6 months in the previous study</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, postmenopausal women

          -  Randomized to either denosumab or placebo in the 20050179 (NCT00293813) study and
             completed that study (ie, attended an end of study visit)

          -  At least 12 months have elapsed since their end of 20050179 study visit

          -  Provide signed informed consent

        Exclusion Criteria:

          -  Subjects who failed to receive both doses of denosumab (or SQ [subcutaneous] placebo)
             during the 20050179 study

          -  Subjects who were randomized to the alendronate arm during the 20050179 study

          -  Subjects diagnosed with any of the following conditions following completion of the
             20050179 study:

          -  Hyperthyroidism

          -  Hyperparathyroidism

          -  Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell
             carcinoma)

          -  Any condition that required chronic (greater than three months cumulative and greater
             than 5 mg/day) glucocorticoid therapy

          -  Other diseases which affect bone metabolism

          -  Self-reported alcohol or drug abuse within the previous 12 months

          -  Any disorder that, in the opinion of the investigator, may compromise the ability of
             the subject to give written informed consent and/or comply with study procedures

          -  Received any investigational product other than denosumab in two years before the
             screening visit.

          -  Received &gt; 3 months (or equivalent) of osteoporosis treatment since having completed
             the 20050179 study.

          -  Current use of the following osteoporosis agents: bisphosphonates, calcitonin,
             fluoride, parathyroid hormone analogue, selective estrogen receptor modulators,
             systemic oral or transdermal estrogen (except vaginal preparations and estrogen creams
             which are acceptable), strontium or tibolone.

          -  Currently enrolled in or has not yet completed at least 1 month since ending other
             investigational device or drug trial(s) (other than Amgen trial 20080287), or subject
             is receiving other investigational agent(s).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>concept.747 Treatment/discontinuation on wrist.Journal-004521;</citation>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2009</study_first_posted>
  <results_first_submitted>June 30, 2011</results_first_submitted>
  <results_first_submitted_qc>June 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2011</results_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject enrolled on 14-JUL-2009. The last subject enrolled on 12-MAY-2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Previous Placebo Treatment Group</title>
          <description>Participants who had previously received placebo and completed Study 20050179 (NCT00293813). No study drug was administered during this study.</description>
        </group>
        <group group_id="P2">
          <title>Previous Denosumab Treatment Group</title>
          <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Previous Placebo Treatment Group</title>
          <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
        </group>
        <group group_id="B2">
          <title>Previous Denosumab Treatment Group</title>
          <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="5.8"/>
                    <measurement group_id="B2" value="63.4" spread="6.5"/>
                    <measurement group_id="B3" value="63.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months since last dose in 20050179</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="2.5"/>
                    <measurement group_id="B2" value="32.2" spread="2.7"/>
                    <measurement group_id="B3" value="32.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT</title>
        <description>Percent change from the 20050179 Baseline in cortical thickness at the distal radius as determined by high-resolution peripheral quantitative computed tomography (HR-pQCT) at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT</title>
          <description>Percent change from the 20050179 Baseline in cortical thickness at the distal radius as determined by high-resolution peripheral quantitative computed tomography (HR-pQCT) at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" lower_limit="-8.3" upper_limit="-2.8"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-4.8" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear, quadratic and cubic time terms with treatment-by-time interaction</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0766</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT</title>
        <description>Percent change from the 20050179 Baseline in total BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT</title>
          <description>Percent change from the 20050179 Baseline in total BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-2.6" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.2" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1648</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT</title>
        <description>Percent change from the 20050179 Baseline in cortical BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT</title>
          <description>Percent change from the 20050179 Baseline in cortical BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-1.7" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.8" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear, quadratic and cubic time terms but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0228</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT</title>
        <description>Percent change from the 20050179 Baseline in trabecular BMD at the distal radius as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT</title>
          <description>Percent change from the 20050179 Baseline in trabecular BMD at the distal radius as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="2.3" upper_limit="8.0"/>
                    <measurement group_id="O2" value="5.9" lower_limit="2.8" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model includes linear, quadratic and cubic time terms but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6560</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT</title>
        <description>Percent change from the 20050179 Baseline in cortical thickness at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT</title>
          <description>Percent change from the 20050179 Baseline in cortical thickness at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" lower_limit="-7.8" upper_limit="-5.1"/>
                    <measurement group_id="O2" value="-4.6" lower_limit="-5.9" upper_limit="-3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0594</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT</title>
        <description>Percent change from the 20050179 Baseline in total BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT</title>
          <description>Percent change from the 20050179 Baseline in total BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-2.8" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.2" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT</title>
        <description>Percent change from the 20050179 Baseline in cortical BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT</title>
          <description>Percent change from the 20050179 Baseline in cortical BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-1.7" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-1.4" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear, quadratic and cubic time terms but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2897</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT</title>
        <description>Percent change from the 20050179 Baseline in trabecular BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT</title>
          <description>Percent change from the 20050179 Baseline in trabecular BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="6.8" lower_limit="4.9" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA</title>
        <description>Percent change of distal 1/3 radius BMD from the 20050179 Baseline as determined by dual energy X-ray absorptiometry (DXA) at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA</title>
          <description>Percent change of distal 1/3 radius BMD from the 20050179 Baseline as determined by dual energy X-ray absorptiometry (DXA) at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.3" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.2" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0184</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA</title>
        <description>Percent change of ultradistal radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since last the subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA</title>
          <description>Percent change of ultradistal radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since last the subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-4.9" upper_limit="-2.2"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-3.3" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0911</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Total Radius BMD From the Parent Study Baseline by DXA</title>
        <description>Percent change of total radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
        <time_frame>Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Total Radius BMD From the Parent Study Baseline by DXA</title>
          <description>Percent change of total radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.</description>
          <population>Participants with observed data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-4.0" upper_limit="-2.0"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-1.9" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance model was fit with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual Value of Serum Type I C-telopeptide</title>
        <description>Actual value of Serum Type I C-telopeptide measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual Value of Serum Type I C-telopeptide</title>
          <description>Actual value of Serum Type I C-telopeptide measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).</description>
          <population>Participants with observed data.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.5" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.6" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA based on the log transformed actual values with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0591</p_value>
            <method>ANCOVA</method>
            <param_type>Ratio of Denosumab to Placebo</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual Value of Procollagen Type 1 N-terminal Peptide</title>
        <description>Actual value of Type 1 N-terminal Peptide as measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Previous Placebo Treatment Group</title>
            <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
          <group group_id="O2">
            <title>Previous Denosumab Treatment Group</title>
            <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual Value of Procollagen Type 1 N-terminal Peptide</title>
          <description>Actual value of Type 1 N-terminal Peptide as measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).</description>
          <population>Participants with observed data.</population>
          <units>g/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" lower_limit="45.6" upper_limit="54.3"/>
                    <measurement group_id="O2" value="58.9" lower_limit="54.1" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA based on the log transformed actual values with main effects for randomized treatment in study 20050179, baseline value, time since last subcutaneous dose of denosumab or placebo in study 20050179 as a continuous variable, and the age stratification from 20050179. Model included linear time term but without treatment-by-time interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>ANCOVA</method>
            <param_type>Ratio of Denosumab to Placebo</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs (serious only) were collected after informed consent and through 30 days after the study procedures, maximum time on study was 44 days.</time_frame>
      <desc>Only Serious Adverse Events were collected for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Previous Placebo Treatment Group</title>
          <description>Participants who had previously received placebo and completed Study 20050179. No study drug was administered during this study.</description>
        </group>
        <group group_id="E2">
          <title>Previous Denosumab Treatment Group</title>
          <description>Participants who had previously received denosumab and completed Study 20050179. No study drug was administered during this study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

